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Background: Mucopolysaccharidoses (MPS) are severe metabolic disorders caused by accumulation of undegraded
glycosaminoglycans (GAGs) in lysosomes due to defects in certain lysosomal hydrolases. Substrate reduction
therapy (SRT) has been proposed as one of potential treatment procedures of MPS. Importantly, small molecules
used in such a therapy might potentially cross the blood–brain barrier (BBB) and improve neurological status of
patients, as reported for a natural isoflavone, 5, 7-dihydroxy-3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one, also
known as genistein. Although genistein is able to cross BBB to some extent, its delivery to the central nervous
system is still relatively poor (below 10% efficiency). Thus, we aimed to develop a set of synthetically modified
genistein molecules and characterize physicochemical as well as biological properties of these compounds.
Methods: Following parameters were determined for the tested synthetic derivatives of genistein: cytotoxicity,
effects on cell proliferation, kinetics of GAG synthesis, effects on epidermal growth factor (EGF) receptor’s tyrosine
kinase activity, effects on lysosomal storage, potential ability to cross BBB.
Results: We observed that some synthetic derivatives inhibited GAG synthesis similarly to, or more efficiently than,
genistein and were able to reduce lysosomal storage in MPS III fibroblasts. The tested compounds were generally of
low cytotoxicity and had minor effects on cell proliferation. Moreover, synthetic derivatives of genistein revealed
higher lipophilicity (assessed in silico) than the natural isoflavone.
Conclusion: Some compounds tested in this study might be promising candidates for further studies on
therapeutic agents in MPS types with neurological symptoms.
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Mucopolysaccharidoses (MPS) are rare lysosomal stor-
age disorders caused by deficiencies in activities of
several different lysosomal hydrolases. Mutations in
genes coding for these enzymes lead to defects in deg-
radation of glycosaminoglycans (GAGs) [1,2]. Excessive
accumulation of undegraded GAGs in lysosomes causes
severe problems in most tissues and organs and usually
leads to death in childhood [2]. Currently, only two
therapeutic procedures are available for treatment of
some of MPS types: bone marrow (or hematopoietic
cell) transplantation and enzyme replacement therapy* Correspondence: wegrzyn@biotech.univ.gda.pl
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reproduction in any medium, provided the or(ERT) [3]. The former procedure is the therapy of choice
in MPS I, as it can halt neurocognitive decline when
performed early, preferably before the age of 2.5 years
[4]. However, efficacy has only been demonstrated in
MPS I and MPS VI, and not in MPS III [3,4]. The latter
treatment is based on administration of the lacking
enzyme, and it is currently available for MPS I, MPS II
and MPS VI [5]. Although this treatment is to some ex-
tent effective in management of somatic symptoms of
the disease, in many MPS types (MPS IH, MPS II, all
MPS III subtypes, MPS VII) central nervous system
(CNS) is also affected, and ERT seems to be of low effi-
cacy in treatment of neurological symptoms because of
the poor delivery of enzyme molecules to CNS across
the blood–brain barrier (BBB) [4,6].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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alternative methods for MPS treatment [6]. A specific
kind of SRT for MPS, based on administration of
genistein (5, 7-dihydroxy-3- (4-hydroxyphenyl)-4H-
1-benzopyran-4-one also known as 4', 5, 7-
trihydroxyisoflavone), has been proposed [7]. In vitro, genis-
tein significantly inhibits GAG synthesis and results in a de-
crease in lysosomal storage in MPS cells [7]. Expression of
genes coding for enzymes involved in GAG synthesis might
be controlled by signalling pathways dependent on a tyro-
sine kinase activity of epidermal growth factor receptor
(EGFR) [8,9], and genistein has been reported to inhibit this
enzymatic activity [10]. In fact, genistein-mediated SRT was
reported to act due to inhibition of phosphorylation of
EGFR [11] and subsequent putative modulation of gene ex-
pression. Therefore, this specific kind of SRT has been
named ‘gene expression-targeted isoflavone therapy’ or
GET IT [12-14].
Since genistein was reported to cross the BBB to some
extent [15], it has been suggested that GET IT might be
effective in treatment of neurological symptoms of MPS.
In fact, in vivo studies performed with MPS IIIB mouse
model revealed a significant reduction of lysosomal stor-
age in liver of MPS IIIB mice treated with genistein for
8 weeks [16], and correction of the abnormal behavior in
a long-term (9 month) experiment with high genistein
dose (160 mg/kg/day) [17]. Additionally, in both open
label and placebo-controlled studies with MPS III
patients treated with a genistein-rich soy extract at rela-
tively low doses (5–15 mg/kg/day), some – though only
limited – positive effects on urinary and plasma GAG
levels, hair morphology, cognitive functions and behav-
ior were reported [18-22]. This low efficacy of GET IT
in clinical trials, which is in contrast to promising results
of experiments performed in vitro and with mice, has re-
cently been suggested to be due to low genistein doses
in former studies (5–15 mg/kg/day in clinical studies vs.
160 mg/kg/day in animal-based experiments) [14].
Nevertheless, other mechanisms, like limited effects of
genistein in human body and/or low efficiency of cross-
ing BBB by this isoflavone (this efficiency was estimated
to be below 10% in rats [15]), could not be excluded.
Simultaneously to clinical trials, further laboratory ex-
periments on GET IT have been performed and it was
demonstrated that some other natural isoflavones, or even
flavonoids, may also cause an inhibition of GAG synthesis
and reduction of their accumulation in MPS cells [23,24].
Therefore, one might speculate that chemical modifica-
tion(s) of genistein might improve either its efficiency in
GAG synthesis inhibition or efficiency in crossing BBB. If
so, GET IT could be of higher efficacy in MPS patients.
In this study, we aimed to test a series of synthetic deri-
vatives of genistein in terms of efficiency of GAG synthe-
sis inhibition and potential ability to cross BBB.Methods
Chemicals
Genistein was obtained at the Pharmaceutical Research
Institute (Warsaw, Poland) on the pilot plant scale, ac-
cording to proprietory method [25]. A method for re-
gioselective derivatization of its phenolic groups was
designed, based on unique, stable tetrabutylammonium
salt [26]. Preparations of its synthetic derivatives were
already described in connection with study of antiproli-
ferative activity [27]. The derivatives listed in Table 1
have also been claimed as modulators of GAG storage
in CNS (United States Patent no. US 8,178,609 B2; date
of patent: May 15, 2012; inventors: Grynkiewicz G.,
Wegrzyn G., Szechner B., Tylki-Szymanska A., Wegrzyn
A., Jakobkiewicz-Banecka J., Baranska S., Czartoryska B.,
Piotrowska E., title: Isoflavones for treating muco-
polysaccharidoses). Stock solutions were prepared in
dimethylformamide (DMF). MTT reagent (3-(4,5-
dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide),
purchased from Sigma (Germany), was dissolved in
RPMI-1640 medium without phenol red (Sigma,
Germany). Phosphate Bufered Saline (PBS), dimethylsulf-
oxide (DMSO) and dimethylformamide (DMF) were
from Sigma (Germany).Cell lines and culture conditions
Fibroblast cell lines obtained fromMPS IIIA andMPS IIIB
patients were used in all experiments. Human Dermal
Fibroblast adult line (HDFa; Cascade Biologics, Portland,
OR, USA) was used as a healthy control line. Cells were
grown in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% Fetal Bovine Serum (FBS) and 1 x
Antibiotic and Antimycotic Solution (all purchased from
Sigma, Germany) at 37 °C in humidified 5% CO2 atmos-
phere. GAG synthesis experiments were performed using
Minimal Essential Medium without inorganic sulfates
(MEM, Joklik’s modified; Sigma, Germany).Cytotoxicity and proliferation assay
Cytotoxicity and cell proliferation was assessed using
MTT assay. Cells were seed in 96-well plates in a num-
ber of 6 x 103 cells per well (cytotoxicity assay) or 103
cells per well (proliferation assay). After an overnight in-
cubation, growth medium was substituted with medium
supplemented with appropriate concentrations of genis-
tein synthetic derivatives or 0.05% DMF as a control and
cells were incubated for 24- or 48-hours (cytotoxicity
assay) or for 7-days (proliferation assay). Then, medium
was substituted with MTT solution (1 mg/ml in RPMI-
1640 medium) and following 2-hour incubation at 37°C
the amount of a purple formazan product dissolved in
DMSO was quantified by measuring the absorbance at
550 nm. LC50 (cytotoxicity assay) or IC50 (proliferation
Table 1 Synthetic derivatives of genistein
Symbol IUPAC systematic name Molecular
formula
Molecular
weight
IFG-001 4-(5,7-dihydroxy-4-oxo-4 H-chromen-3-yl)phenyl 2-aminobenzoate C22H15NO6 389.367
IFG-018 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4 H-chromen-7-yl heptadecanoate C31H40O6 508.65
IFG-021 7-O-[(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-1,4-(6-O-acetyl-hex-2-ene-α-D- erythropyranosyl)]-5-hydroxy-3-
(4-hydroxyphenyl)-4-H-chromen-4-one
C37H38O18 770.689
IFG-027 5-hydroxy-3-(4-hydroxyphenyl)-7-(prop-2-en-1- yloxy)-4 H-chromen-4-one C18H14O5 310.30
IFG-032 4-[5,7-bis(acetyloxy)-4-oxo-4 H-chromen-3-yl]phenyl acetate C21H16O8 396.35
IFG-034 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4 H-chromen-7-yl)-2-acetyloxybenzoate C24H16O8 432.39
IFG-035 5,7-bis(prop-2-en-1-yloxy)-3-[4-(prop-2-en-1- yloxy)phenyl]-4 H-chromen-4-one C22H22O5 390.43
IFG-036 ethyl 2-((5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4 H-chromen-7-yl)oxy)acetate C19H16O7 356.33
IFG-037 tert-butyl-2-((5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4 H-chromen-7-yl)oxy)acetate C21H20O7 384.382
IFG-038 tetrabutylamonium 5-{[5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4 H-chromen-7-yl]oxy}-5-oxopentanoate C36H51NO8 625.1
IFG-042 tert-butyl 2-[(3-{4-[2-(tert-butoxy)-2- oxoethoxy]phenyl}-5-hydroxy-4-oxo-4 H-chromen-7-yl)oxy]acetate C27H30O9 498.52
IFG-043 tert-butyl 2-[(3-{4-[2-(tert-butoxy)-2-oxoethoxy]phenyl}-5-hydroxy-4-oxo-4 H-chromen-7-yl)oxy]acetate C22H16O5 360.36
IFG-046 2(2(2-((4-oxo-4 H-chromen-7-yl)oxy)ethoxy)ethoxy)ethyl)-4-methylbenzenesulfonate C28H28O10S 556.14
IFG-048 tert-butyl 2-[4-(5,7-dihydroxy-4-oxo-4 H-chromen-3-yl)phenoxy]acetate C21H20O7 384.382
IFG-050 5-hydroxy-3-(4-hydroxyphenyl)- 7-O-(epoxymethyl)- 4-H-chromen-4-one C18H14O6 326.30
IFG-051 7-(benzyloxy)-5-hydroxy-3-[4-(prop-2-en-1- yloxy)phenyl]-4 H-chromen-4-one C25H20O5 400.42
IFG-052 4-[5-hydroxy-4-oxo-7-(prop-2-en-1-yloxy)-4 H- chromen-3-yl]phenyl 2-(acetyloxy)benzoate C27H20O8 472.44
IFG-053 2-(3-{4-[7-(benzyloxy)-5-hydroxy-4-oxo-4 H-chromen-3-yl]phenoxymethyl}-5-(1-cyano-1-methylethyl)phenyl)-2-
methylpropanenitrile
C37H32N2O5 584.66
IFG-054 2-{[5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4 H-chromen-7-yl]oxy}acetic acid C17H12O7 328.27
IFG-060 5-{4-[7-(benzyloxy)-5-hydroxy-4-oxo-4 H-chromen-3-yl]phenoxy}-5-oxopentanoic acid C27H22O8 474.47
IFG-061 4-[7-(benzyloxy)-5-hydroxy-4-oxo-4 H-chromen-3-yl]phenyl 1-sodium pentanedioate C27H21O8Na 480.45
IFG-062 5-hydroxy-3-(4-hydroxyphenyl)-7-[(4- methoxyphenyl)methoxy]-4 H-chromen-4-one C23H18O6 390.39
IFG-063 [5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4 H-chromen-7-yl] prop-2-en-1-yl carbonate C19H14O7 354.31
IFG-064 7-(benzyloxy)-5-hydroxy-3-[4-(propan-2- yloxy)phenyl]-4 H-chromen-4-one C25H22O5 402.44
IFG-065 7-(benzyloxy)-5-(propan-2-yloxy)-3-[4-(propan-2-yloxy)phenyl]-4 H-chromen-4-one C28H28O5 444.52
IFG-066 5,7-dihydroxy-3-[4-(propan-2-yloxy)phenyl]-4 H- chromen-4-one C18H16O5 312.32
IFG-067 4-[7-(benzyloxy)-5-hydroxy-4-oxo-4 H-chromen-3-yl]phenyl acetate C24H18O6 402.4
IFG-070 methyl 2-{[5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4 H-chromen-7-yl]oxy}acetate C18H14O7 342.16
IFG-071 5-{[5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4 H-chromen-7-yl]oxy}pentyl acetate C22H22O7 398.40
IFG-072 5-hydroxy-3-(4-hydroxyphenyl)-7-(3-hydroxypropoxy)-4 H-chromen-4-one C18H16O6 328.31
IFG-073 5-hydroxy-7-(2-hydroxyethoxy)-3-(4-hydroxyphenyl)-4 H-chromen-4-one C17H14O6 314.22
IFG-074 tetrabutylamonium 2-{[5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4 H-chromen-7-yl]oxy}acetate C33H47O7N 569.73
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treated cultures (incubated with DMF only).
Measurement of kinetics of GAG synthesis
Cells seed in a number of 2 x 104 cells per well (48-well
plate) were incubated in growth medium overnight.
Then, the medium was substituted with another one,
containing appropriate concentrations of genistein syn-
thetic derivatives or 0.05% DMF as a control, and cells
were grown for 48 hours. In the next step, the medium
was substituted with growth medium without inorganicsulfates (MEM, Joklik’s modified) mixed with standard
DMEM medium (1:1) supplemented with FBS. GAGs
were labeled with 20 μCi/ml of H2[
35 S]O4 (Hartmann
Analytic) for 24 hours. Cells washed with PBS were
digested for 3 hours with 0.03% papain (prepared in
100 mM sodium acetate with 5 mM L-cysteine, pH 7.0)
(Merck KGaA, Darmstadt, Germany). 35 S incorporation
was measured in a scintillation counter and calculated
per DNA amount, which was determined in samples
with Quant-iT™ PicoGreenW dsDNA Reagent (Molecular
Probes, Inc.) according to the manufacturer’s protocol.
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Cells were seed in a number of 104 cells per well of 96-
well plate. Following an overnight incubation, standard
growth medium was substituted with the medium sup-
plemented with appropriate concentrations of genistein
synthetic derivatives or a potent tyrosine kinase inhibitor
PD168390 (Merck KGaA, Darmstadt, Germany), and
cells were incubated for 2 hours. Then, Epidermal
Growth Factor (BD Biosciences, Franklin Lakes, NJ
USA) was added to 100 ng/ml to induce EGF receptor
autophosphorylation. After 15 min the medium was
removed, and cells were fixed with 4% formaldehyde.
Tyrosine kinase activity of EGF receptor was assessed
using commercially available Cell-Based ELISA, Human
Phospho-EGFR (Y1068) Immunoassay (R&D Systems,
Inc) according to the manufacturer’s protocol.Electron microscopic studies
Cells were incubated in growth medium supplemented
with appropriate concentrations of tested compounds
for 6 days. Following PBS washing, cells were fixed with
2.5% glutaraldehyde, and then with 1% osmium tetroxide
and 1% potassium hexacyanoferrate (III) followed by
ethanol dehydration. Sections of Epon 812 resin (Fluka,
Germany) embedded cells were stained in lead citrate
and uranyl acetate and examined under transmission
electron microscope (Philips CM100). The number of
different lysosomal structures was determined.Computational prediction of BBB penetration
Following physicochemical parameters were determined
for each synthetic derivative of genistein: molecular weight
(MW), octanol/water partition coefficient (cLogP), topo-
logical polar surface area (tPSA), the number of hydro-
gen bond donors (HBD) and hydrogen bond acceptors
(HBA). Calculation of cLogP was performed on the basis
of the chemical structure of compounds using ALOGPS
2.1 Program (VCCLAB) accessible via Internet (http://
www.vcclab.org) and assessment of tPSA was performed
with MarvinSketch 5.2.6 (ChemAxon Ltd.) accessible via
Internet (http://intro.bio.umb.edu/111-112/OLLM/111F98/
newclogp.html). Predicted logBB was assessed as pro-
posed previously [28].Statistical analysis
Effects of different concentrations of genistein synthetic
derivatives on the number of lysosomal structures was
tested by one-way ANOVA with Tukey’s multiple com-
parisions as a post-hoc test. Statistical tests were per-
formed using Statistica 8.0 [StatSoft, Poland] software
with significance at p< 0.05.Results
Cytotoxicity and antiproliferative activity of genistein
synthetic derivatives
We have tested 32 synthetic derivatives of genistein in
order to establish cytotoxicity and antiproliferative activ-
ity in cultured fibroblasts after 24 h exposition to these
compounds in a concentration range 1–30 μM. We found
toxicity of several synthetic derivatives as low as that of
genistein (compounds: IFG-032, IFG-034, IFG-036, IFG-
038, IFG-053, IFG-054, IFG-066, IFG-070, IFG-071, IFG-
072), while others exhibited higher cytotoxicity (see LC50
values, Table 2). Additionally, most of the compounds
with low cytotoxicity (excluding IFG-053 and IFG-070)
exhibited antiproliferative activity similar to or lower
than that of genistein (see IC50 values, Table 2).
Reduction of GAG synthesis by some genistein synthetic
derivatives
Since genistein inhibits GAG synthesis in a dose-
dependent manner, we have tested the effects of 32
genistein synthetic derivatives on GAG synthesis in fi-
broblast cultures. The level of GAG synthesis was es-
timated by measurement of [35 S]O4
2- uptake. Different
genistein synthetic derivatives revealed various ability
to inhibit GAG synthesis, though six of them (IFG-
032, IFG-038, IFG-042, IFG-043, IFG-061, IFG-071)
decreased GAG synthesis after 3-day exposure to ex-
tent similar to that of genistein, while two (IFG-060,
IFG-066) were even more effective (Table 2). Interest-
ingly, some compounds (IFG-001, IFG-046, IFG-051,
IFG-054, IFG-062, IFG-064) stimulated rather than in-
hibited GAG synthesis, with IFG-062 being a strong
(over 4-fold) stimulator (Table 2).
Decrease of lysosomal storage of GAGs by some
genistein synthetic derivatives
For further studies, we have selected the derivatives
which revealed: (i) low cytotoxicity, (ii) antiproliferative
activity similar to genistein, and (iii) efficient inhibition
of GAG synthesis. Assuming that reduction in GAG syn-
thesis may lead to a decrease in lysosomal storage, as
concluded previously [13,14], we assessed the storage in
MPS cells by using electron microscopic techniques.
The number of different lysosomal structures were
counted and calculated per 100 μm2 of cell cross-
section. Examples of abnormal storage structures,
observed in MPS IIIA and MPS IIIB cells, are presented
in Figure 1.
We have observed a statistically significant decrease
in the number of different abnormal lysosomal struc-
tures in MPS IIIA or MPS IIIB fibroblasts after 6-day
exposure to all selected genistein synthetic derivatives
at 30 μM, relative to untreated cells (Table 3). Average
size of these structures did not change significantly
Table 2 Cytotoxic and antiproliferative activities of genistein synthetic derivatives and their effects on kinetics of GAG
synthesis in fibroblasts
Compound Cytotoxicity LC50 [μM] Proliferation IC50 [μM] GAG synthesis [%]
IFG-001 13.9 - 120± 56
IFG-018 41.7 - 76 ± 38
IFG-021 11.0 - 75 ± 25
IFG-027 13.1 - 69 ± 46
IFG-032 n/c 17.4 57 ± 24
IFG-034 n/c 22.9 65 ± 19
IFG-035 22.6 - 93 ± 70
IFG-036 n/c 11.2 64 ± 21
IFG-037 23.5 - 88 ± 84
IFG-038 n/c 19.9 55 ± 13
IFG-042 22.0 - 48 ± 29
IFG-043 14.5 - 46 ± 41
IFG-046 20.7 - 118± 72
IFG-048 20.3 - 73 ± 5
IFG-050 11.6 - 100± 65
IFG-051 14.6 - 127± 109
IFG-052 15.8 - 74 ± 19
IFG-053 n/c 53.0 92 ± 52
IFG-054 n/c n/a 119± 64
IFG-060 14.9 - 31 ± 8
IFG-061 18.8 - 50 ± 25
IFG-062 12.1 - 403± 206
IFG-063 51.5 - 76 ± 6
IFG-064 6.6 - 133± 77
IFG-065 22.7 - 96 ± 22
IFG-066 n/c 14.6 34 ± 10
IFG-067 15.1 - 96 ± 38
IFG-070 n/c 48.1 101± 30
IFG-071 n/c 17.9 49 ± 20
IFG-072 n/c 14.1 79 ± 42
IFG-073 27.5 - 83 ± 32
IFG-074 44.1 - 88 ± 39
Genistein n/c 16.9 55 ± 31
Cytotoxicity is expressed as LC50 index value, i.e. concentration of the tested drug [μM] that is lethal to 50% of cells in a culture exposed to the tested compound
for 24 hours. Antiproliferative activity is expressed as IC50 index value, i.e. concentration of the tested drug [μM] that causes 50% inhibition of cell proliferation in
a culture exposed to the tested compound for 7 days. Kinetics of GAG synthesis is expressed as relative 35 S incorporation into GAGs after 3-day exposure to
derivatives of genistein at 30 μM concentration. Labeling was conducted for 24 hours with 20 μCi/ml H2[
35 S]O4. Radioactivity of incorporated
35 S was measured
in a scintillation counter, calculated per DNA amount [dpm/ng DNA] and expressed as the percentage of control, where 100% corresponds to the relative 35 S
incorporation into control (cell culture treated with 0.05% dimethylformamide).
n/c denotes experiments in which no cytotoxicity was observed (over 90% of cells survived at concentrations ranging from 1 to 30 μM).
n/a denotes experiments in which no antiproliferative activity was observed (relative proliferation was over 95% at concentrations ranging from 1 to 30 μM).
- denotes experiments in which IC50 for antiproliferative activities could not be determined due to cytotoxic effects of the tested compounds.
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like structures of unknown function or content, were
observed in cells treated with compound IFG-066
(Figure 1D).Phosphorylation of EGF receptor in the presence of
genistein synthetic derivatives
Reduction of GAG synthesis is assumed to be the result
of impaired expression of genes coding for enzymes
1 m 2 m
A B
2 m
C
2 m
D
Figure 1 Electron microphotographs of different types of lysosomal structures in MPS III fibroblasts: lysosome with lamellar and
electron-dense structure (A), lysosome of amorphous, flocculent and electron-lucent structure (B), complexed lysosomal structure
(autophagolysosome) with storage material of different electron density (C), and vacuoles of unknown origin and function (D).
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lular signaling pathway depending of tyrosine kinase ac-
tivity of EGFR [13,29]. Since genistein was reported to
inhibit the activity of tyrosine kinase of EGFR, and thusTable 3 Effect of synthetic derivatives of genistein at 30 μM c
structures in MPS IIIA and MPS IIIB fibroblasts
Compound Number of structure
lamellar complexed
None 0.40 ± 0.17 0.35 ± 0.35
IFG-032 0.14 ± 0.08 * 0.22 ± 0.11
IFG-034 0.17 ± 0.09 * 0.27 ± 0.14
IFG-036 0.19 ± 0.14 * 0.28 ± 0.16
IFG-038 0.32 ± 0.16 0.27 ± 0.13
IFG-066 0.13 ± 0.10 * 0.16 ± 0.08
IFG-071 0.28 ± 0.13 0.26 ± 0.09
IFG-072 0.20 ± 0.10 * 0.28 ± 0.10
None 0.44 ± 0.18 0.14 ± 0.10
IFG-032 0.17 ± 0.11 * 0.10 ± 0.07
IFG-034 0.20 ± 0.16 * 0.06 ± 0.05
IFG-036 0.25 ± 0.21 * 0.12 ± 0.11
IFG-038 0.21 ± 0.12 * 0.10 ± 0.10
IFG-066 0.15 ± 0.10 * 0.11 ± 0.14
IFG-071 0.07 ± 0.07 * 0.07 ± 0.06
IFG-072 0.11 ± 0.12 * 0.16 ± 0.08
Asterisks (*) indicate statistically significant differences (one-way ANOVA with Tukey
IIIA and MPS IIIB cells (None) where no tested compound was added into culture mto impair production of GAGs, we have tested the ability
of some genistein synthetic derivatives (able to inhibit
GAG synthesis) to impair phsophorylation of EGFR. We
have observed that none of the tested synthetic derivativesoncentration on the number of different lysosomal
s per 100 μm2 of cellular cross section± SD
amorphous total number
MPS IIIA
0.38 ± 0.27 1.13 ± 0.50
0.17 ± 0.16 * 0.53 ± 0.19 *
0.17 ± 0.09 * 0.61 ± 0.20 *
0.22 ± 0.11 0.73 ± 0.31 *
0.21 ± 0.13 0.80 ± 0.24 *
0.18 ± 0.19 * 0.48 ± 0.17 *
0.25 ± 0.11 0.79 ± 0.22 *
0.34 ± 0.17 0.82 ± 0.23
MPS IIIB
0.17 ± 0.12 0.75 ± 0.31
0.12 ± 0.08 0.40 ± 0.20 *
0.15 ± 0.08 0.41 ± 0.16 *
0.15 ± 0.18 0.50 ± 0.34
0.09 ± 0.09 0.41 ± 0.18 *
0.08 ± 0.06 0.34 ± 0.23 *
0.13 ± 0.09 0.26 ± 0.13 *
0.14 ± 0.10 0.41 ± 0.20 *
’s multiple comparisions as a post-hoc test, p< 0.05) relative to control MPS
edium.
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Comparing to genistein or a potent tyrosine kinase in-
hibitor PD168390, no decrease of phosphorylation of
EGFR was observed (Figure 2), suggesting that the syn-
thesis of GAGs is reduced by investigated compounds by
some other, unknown, mechanism(s).
Computational prediction of BBB penetration
Because genistein was reported to cross BBB only to
some extent (several percent efficiency) we aimed to de-
velop new derivatives of genistein with more lipophilic
properties that could be able to cross this barrier more
readily. Chemical modifications of the genistein molecule
resulted, in most of the cases, in an increase of cLogP
values, suggesting an increase in lipophilicity (Table 4).
Moreover, some of genistein derivatives revealed tPSA
values optimal for compounds able to cross BBB
(tPSA < 90 Å2) (Table 4). These results suggest a pos-
sible improvement in physicochemical properties of
some modified genistein molecules compared to un-
modified ones, in the light of efficiency of crossing BBB.
Discussion
An important issue in development of therapeutic
approaches for MPS types with neurological symptoms
is the ability of potential therapeutic agents to cross
BBB. Enzyme replacement therapy, a treatment based on
systematic, intravenous administration of the lacking en-
zyme, although effective - to some extent - in treatment
of visceral organs, is of low efficacy in treatment of casesConcentration of
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Figure 2 Effect of selected synthetic derivatives of genistein on the a
phosphorylation relative to untreated control cells (ctrl), genistein (Genist) a
deviation between two independent experiments, is presented. Statistically
phosphorylation, relative to the control cells (ctrl) was detected only for gewhere the central nervous system is affected [1,6]. Alter-
native therapeutic approaches, such as substrate
reduction therapies, are based on assumptions that low-
molecular-weight molecules might be able to cross BBB
and penetrate the brain readily [29].
The results presented in this report indicate that some
synthetic derivatives of genistein, particularly, IFG-060
and IFG-066, are potent inhibitors of GAG synthesis.
Impairment of GAG synthesis by IFG-032, IFG-034,
IFG-036, IFG-038, IFG-066, IFG-071 and IFG-072 was
also an effective method for reduction of lysosomal stor-
age in MPS IIIA and/or MPS IIIB cell cultures, as it was
previously reported for genistein [7]. Studies on MPS
IIIB mice suggested that GET IT may be a promising
treatment [16,17]. Thus, according to results obtained in
this study, we suggest that artificial genistein derivatives
listed in Table 3 might be considered as potential drugs
to be used in treatment of MPS.
In the development of new therapies, it is crucial for a
potential drug to be safe for humans. In this study, some
synthetic derivatives of genistein (including the efficient
reducers of GAG storage, listed in Table 3) revealed low
cytotoxicity and minor effects on cell proliferation. This
appears important in the light of safety problems with
another effective inhibitor of GAG synthesis, rhodamine
B [30,31]. Therefore, it seems that some derivatives of
genistein (e.g. IFG-032, IFG-034, IFG-036, IFG-038,
IFG-066, IFG-071, IFG-072) possess desirable biological
properties for a potentially safe and effective drug. More-
over, predicted changes of physicochemical properties ofIFG-072 Genist Inh
 tested compound [ M]
IFG-071IFG-066IFG-052
30 30 0.110    3010     3030
ctivity of tyrosine kinase of EGF R. Relative levels of EGF R
nd artificial inhibitor - PD168390 (Inh), with bars indicating standard
significant (p< 0.05) decrease in relative level of EGFR
nistein (at 30 μM) and PD168390 (at 0.1 μM).
Table 4 Physicochemical properties of synthetic
derivatives of genistein assessed in silico
Compound MW cLogP tPSA HBA HBD LogBB
Genistein 270.24 2.27 89.82 5 3 −0.86
IFG-001 389.37 4.23 121.91 7 4 −1.12
IFG-018 508.65 8.64 93.06 6 2 0.08
IFG-021 770.69 3.23 235.18 18 2 −2.97
IFG-027 310.30 3.45 75.99 5 2 −0.46
IFG-032 396.35 2.10 105.20 8 0 −1.10
IFG-034 432.39 4.20 119.36 8 2 −0.98
IFG-035 390.43 5.55 53.99 5 0 0.19
IFG-036 356.33 3.04 102.29 7 2 −0.91
IFG-037 384.38 3.85 102.29 7 2 −0.79
IFG-038 625.10 4.11 133.19 8 3 −1.20
IFG-042 498.52 5.44 117.59 9 1 −0.77
IFG-043 360.36 4.40 75.99 5 2 −0.31
IFG-046 556.14 3.74 146.20 10 2 −1.45
IFG-048 384.38 3.85 105.12 7 2 −0.83
IFG-050 326.30 2.64 88.52 6 2 −0.77
IFG-051 400.42 5.58 64.99 5 1 0.03
IFG-052 472.44 5.38 108.36 8 1 −0.64
IFG-053 584.66 8.28 112.57 7 1 −0.26
IFG-054 328.27 2.05 116.12 7 3 −1.27
IFG-060 474.47 4.51 122.19 8 2 −0.98
IFG-061 496.44 3.37 108.36 7 1 −0.95
IFG-062 390.39 4.46 85.22 6 2 −0.44
IFG-063 354.31 3.30 102.29 7 2 −0.87
IFG-064 402.44 5.67 64.99 5 1 0.04
IFG-065 444.52 6.69 53.99 5 0 0.36
IFG-066 312.32 3.54 78.82 5 2 −0.49
IFG-067 402.40 4.43 82.06 6 1 −0.40
IFG-070 342.16 2.67 102.29 7 2 −0.97
IFG-071 398.40 3.92 102.29 7 2 −0.78
IFG-072 328.31 2.44 96.22 6 3 −0.91
IFG-073 314.22 2.17 96.22 6 3 −0.95
IFG-074 569.73 4.17 116.12 7 3 −0.94
MW – molecular weight [Da], cLogP – calculated octanol/water partition
coefficient, tPSA – topological polar surface area [Å2], HBA – hydrogen bond
acceptor number (O +N), HBD – hydrogen bond donor number (OH+NH),
LogBB – predicted BBB permeation.
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sessed in silico), might result in improvement of ability
to cross BBB (see Table 4). On the other hand, it is ne-
cessary to stress that such an improved crossing of BBB
was only calculated in silico by using algorithms based
on putative physicochemical properties of compounds,
predicted from their formulas, according to previously
described models [28]. One has to consider that such anapproach, although based on solid physical and chemical
assumptions, cannot reflect all biological processes,
among which a possible active transport of tested com-
pounds may be especially important. Therefore, it should
be noted that for determination of actual abilities of
penetration of BBB by all compounds described in this
report, it will be necessary to perform experiments with
either BBB models or (preferably) laboratory animals.
Synthesis of labeled isoflavones should be the first step
in the way to assess the real (not only calculated or pre-
dicted) efficiency of BBB penetration by tested genistein
derivatives.
Interestingly, the mechanism of action by which
selected synthetic derivatives of genistein inhibit GAG
production seems to be different from that described
previously for genistein. Namely, contrary to this natural
isoflavone, its artificial derivatives did not affect the
EGF-dependent pathway, as they were not able to inhibit
the EGFR kinase activity. It is worth noting that similar
phenomenon was observed for various natural flavonoids
causing GAG synthesis inhibition [24]. It is, therefore,
tempting to speculate that various chemical modifica-
tions of the genistein molecule destroy its activity of the
EGFR kinase inhibitor, while either retaining/enhancing
or gaining a new function of GAG synthesis inhibitor
by influencing another, as yet unidentified, biochemical
pathway.
Finally, one should note that apart from genistein deri-
vatives that decreased GAG synthesis, there were also
compounds significantly enhancing the efficiency of this
process, like IFG-062. Therefore, we assume that the set
of artificial genistein derivatives described in this report
might be a useful tool in further studies on molecular
mechanisms of regulation of GAG synthesis.
Conclusions
Some synthetic derivaties of genistein revealed low cyto-
toxicity and small (if any) effects on cell proliferation,
while slowing down GAG synthesis (though by a path-
way other than inhibition of EGF receptor’s tyrosine kin-
ase activity) and decreasing lysosomal storage. These
compounds had higher potential abilities to cross BBB
than genistein. Thus, we suggest they are promising can-
didates for further studies on therapeutic agents in MPS
types with neurological symptoms.
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